ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: NIH seeks “visionary thinkers” for awards of $2.5 million over five years. NCI RFA available.

January 23, 2004

Sole Source Negotiations

October 17, 1975

CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely

May 23, 2003

Velcade Addition Can Improve Graft-Versus-Host Outcomes

December 27, 2013

FDA Adopts Final Diagnostics X-Ray Rule Amendment

September 9, 1977

NIEHS Uses Gene Chips To Evaluate Chemicals.

March 3, 2000